Dr.LeslieOBGYN said:

True, and it depends on a baseline nobody has stated.

Can confirm. Same sequence, different timescale. Nothing to add that would improve it.

Dr.LeslieOBGYN said:

True, and it depends on a baseline nobody has stated.

Adding the part of the answer the thread has not reached. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

Happy to go further on any of that.

The figures, for anyone assembling their own picture. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Correct me if the detail matters more than I have assumed.

Following on from Dr.LeslieOBGYN — and this may be the naive question:

Why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose?

LabKate said:

Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Pushing back on LabKate here. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.